Novartis Pelacarsen Fails Phase 3, Sinking Lp(a) Class

Novartis's pelacarsen fails its 8,323-patient Phase 3 cardiovascular trial despite Lp(a) lowering, sending Amgen 10% lower and clouding Lilly's competing pipeline.

Lead

Novartis (NVS) disclosed on September 4 that pelacarsen, an antisense oligonucleotide developed with Ionis Pharmaceuticals (IONS), failed to meet the primary endpoint of the Lp(a)HORIZON Phase 3 trial, which enrolled 8,323 patients with elevated lipoprotein(a) and established cardiovascular disease over six years. The drug lowered Lp(a) concentrations in the treatment arm but produced no statistically significant reduction in the composite primary endpoint of cardiovascular death, non-fatal heart attack, non-fatal stroke, and urgent coronary revascularization requiring hospitalization. NVS erased CHF4.9 billion in market value over the days following the announcement; Amgen (AMGN) fell roughly 10%; Ionis declined approximately 13%; and Eli Lilly (LLY) dropped about 2% as investors reassessed every competing program in the Lp(a) drug class.

Why Did the Drug Lower Lp(a) but Fail to Prevent Events?

The disconnect between biomarker success and clinical failure sits at the core of the pelacarsen setback. Treated patients achieved meaningful reductions in circulating Lp(a), confirming the drug's pharmacological activity, but the enrolled population was simultaneously receiving aggressive guideline-directed therapy - including lipid-lowering agents and antihypertensive drugs - that may have compressed background cardiovascular risk to a level where any additional benefit from Lp(a) reduction became undetectable. The result does not establish whether pelacarsen's antisense mechanism carries a specific ceiling, whether trial design suppressed the signal, or whether lowering Lp(a) simply does not shift outcomes in patients who already have established cardiovascular disease and are on comprehensive standard care.

What Does the Failure Mean for Amgen and Eli Lilly?

The read-through to competitors is significant but not definitive. Amgen's olpasiran, a small interfering RNA therapy, is currently in the Phase 3 OCEAN(a)-Outcomes study, with results awaited. Eli Lilly's pipeline includes two distinct candidates: muvalaplin, the first oral small-molecule Lp(a) inhibitor in Phase 3 testing under the MOVE-Lp(a) trial; and lepodisiran, an siRNA compound that delivered up to 94% Lp(a) reduction with effects persisting more than a year after a single dose in Phase 2. Both companies' drugs differ from pelacarsen in mechanism and appear to achieve deeper, more durable Lp(a) suppression - but they face the identical unresolved clinical question: whether any degree of Lp(a) reduction translates into fewer cardiovascular events in patients already receiving modern standard of care.

Market Reaction and Analyst Sentiment

The announcement triggered broad selling across the cardiovascular drug segment, with the healthcare etf complex absorbing collateral pressure alongside individual pharma and biotech names. For Ionis, the result compounds a difficult stretch: its eplontersen program failed a separate cardiovascular Phase 3 in July 2026, making two major antisense cardiovascular setbacks within three months. Wall Street analysts framed the damage in categorical terms, with Citi concluding that "the first dedicated outcomes failure lowers confidence across the class" while stopping short of abandoning remaining programs. The bank characterized the Lp(a) hypothesis as "weakened, not disproven," preserving analytical space for Amgen and Lilly to salvage the category with their own data.

Is There a Path Forward for the Drug Class?

Mechanistic differences give the category a residual basis for investor interest. Olpasiran and lepodisiran silence the gene encoding apolipoprotein(a) via RNA interference, while muvalaplin physically disrupts Lp(a) particle assembly - both distinct from pelacarsen's antisense approach. Proponents of the remaining programs argue that deeper and more sustained Lp(a) suppression, achievable with newer modalities, may be necessary to clear the outcomes threshold pelacarsen could not reach. The OCEAN(a)-Outcomes readout from Amgen becomes the class's most important near-term inflection point: a positive result would go some distance toward rehabilitating the cardiovascular hypothesis, while a second failure would effectively confirm that reduced Lp(a) does not reliably reduce clinical risk in patients on comprehensive background therapy.

Outlook

Novartis and Ionis face a narrow path for pelacarsen without additional trial modifications or compelling subgroup data from the Lp(a)HORIZON study, removing what had been expected to be a multi-billion-dollar cardiovascular franchise from Novartis's near-term pipeline. Amgen and Lilly retain their programs but carry heightened proof-of-concept risk into readouts the market will treat as binary for the class. A successful OCEAN(a) result would likely restore significant value across Lp(a) drug developers; a second failure would close the chapter on the hypothesis for patients already receiving guideline-directed care.